Analysts expect Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) to announce sales of $14.50 million for the current quarter, according to Zacks. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with the highest sales estimate coming in at $20.00 million and the lowest estimate coming in at $9.00 million. Adaptimmune Therapeutics posted sales of $4.27 million during the same quarter last year, which suggests a positive year over year growth rate of 239.6%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 21st.
According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year sales of $66.26 million for the current financial year, with estimates ranging from $58.03 million to $78.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $27.67 million, with estimates ranging from $24.00 million to $35.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.09. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 41.63%. The business had revenue of $40.79 million for the quarter, compared to analysts’ expectations of $29.41 million.
Shares of NASDAQ:ADAP traded down $0.07 on Friday, reaching $5.43. 618,043 shares of the company were exchanged, compared to its average volume of 523,253. Adaptimmune Therapeutics has a 1-year low of $5.20 and a 1-year high of $14.63. The stock has a market cap of $566.50 million, a PE ratio of -6.79 and a beta of 2.02.
In other Adaptimmune Therapeutics news, Director Ali Behbahani acquired 12,000,000 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were purchased at an average cost of $1.67 per share, with a total value of $20,040,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total transaction of $256,250.00. The disclosure for this sale can be found here. 26.47% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Stanley Laman Group Ltd. acquired a new stake in Adaptimmune Therapeutics in the 3rd quarter valued at about $7,665,000. Bellevue Group AG purchased a new position in Adaptimmune Therapeutics in the 2nd quarter valued at about $711,000. BlackRock Inc. lifted its holdings in Adaptimmune Therapeutics by 2.5% in the 1st quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock valued at $9,062,000 after purchasing an additional 19,765 shares in the last quarter. Creative Planning lifted its holdings in Adaptimmune Therapeutics by 17.5% in the 3rd quarter. Creative Planning now owns 120,900 shares of the biotechnology company’s stock valued at $1,639,000 after purchasing an additional 18,000 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in Adaptimmune Therapeutics by 18.2% in the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares in the last quarter. 60.13% of the stock is currently owned by hedge funds and other institutional investors.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Read More: The Structure of a Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.